Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

The findings come after reports of nasty side effects - including eye problems, infections and gastrointestinal disorders - ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

President Trump's new Executive Order aims to lower prescription drug prices by tying U.S. costs to global rates. Read more ...

In secondary endpoints, 64.6% of participants using Zepbound saw 15% weight loss compared with 40.1% on Wegovy. And Zepbound participants saw their waists reduced by an average 7.2 in (18.4 cm), ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

The first head-to-head trial of two blockbuster weight-loss drugs has shown Mounjaro is more effective than rival Wegovy.

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Interest in weight-loss products continues to surge as calls come for a faster rollout of treatments on the NHS. Research by ...

Weight loss pills either reduce appetite, boost metabolism or block fat absorption. Most people lose 5% to 10% of their body ...